Loading
A phase 1/2 trial in lung cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC is a phase 1/2, interventional study registered as NCT05950139 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 12 participants, started 2024-05-13 and due to reach its primary completion in 2027-07. Interventions recorded: Peptide vaccine. Conditions listed: NSCLC Stage IV; ALK Fusion Protein Expression. Primary outcome: Incidence of treatment-related adverse events; Vaccine-specific immune response. Lung eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of stage IV NSCLC (or recurrent NSCLC not a candidate for definitive multimodality therapy)". Sites: United States. No results are recorded here; the registry entry is the source.
Shares ALK-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares ALK-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares ALK-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares ALK-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares ALK-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares ALK-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares ALK-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.